مكتبة

Source: Human Molecular Genetics EpiHealth: Epidemiology for Health EXODIAB: Excellence of Diabetes Research in Sweden MultiPark: Multidisciplinary research focused on Parkinson´s disease.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

75P PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)

Authors : Liu, S-Y.M.; Zhou, Q.; Du, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102654 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results

Authors : Zhang, Y.; Xie, Y.; Gong, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102767 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

13P Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy

Authors : Han, B.; Zhong, H.; Guo, Q.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102592 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis

Authors : Han, Y.; Xiao, X.; Yao, S.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102726 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

65P Preliminary results of a phase II multicenter, open-label study of fruquintinib monotherapy as third-line treatment in advanced pancreatic cancer

Authors : Guo, W.; Qiong, W.; Wang, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102294 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

Academic Journal

45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors

Authors : Zhu, J.; Song, Z.; Zhao, Y.

Subjects: Cancer Research; Oncology

Source: ESMO Open ; volume 9, page 102274 ; ISSN 2059-7029

تفاصيل العنوان

اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Effects of Maternal Health During Pregnancy and Child Immunization on Mother-to-Child Transmission of Hepatitis B Virus: A Multicentre, Large-Sample Study in Southeast China

Study on Chronic Obstructive Pulmonary Disease and Lung Cancer: Web of Science-Based Bibliometric and Visual Analysis

Correlation Analysis Between Preoperative Serum Iron Level and Prognosis as Well as Recurrence of HCC After Radical Resection

Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk

75P PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)

194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results

13P Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy

139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis

65P Preliminary results of a phase II multicenter, open-label study of fruquintinib monotherapy as third-line treatment in advanced pancreatic cancer

45O First-in-human study of ABSK061: A selective fibroblast growth factor receptor (FGFR) 2/3 inhibitor for treating patients with advanced solid tumors

اتصل بنا

اتبع